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Treatment with a Copper-Zinc Chelator Markedly
and Rapidly Inhibits -Amyloid Accumulation
in Alzheimer’s Disease Transgenic Mice
transgenic mice treated orally for 9 weeks with clioqui-
nol, an antibiotic and bioavailable Cu/Zn chelator. This
was accompanied by a modest increase in soluble A
(1.45% of total cerebral A); APP, synaptophysin, and
GFAP levels were unaffected. General health and body
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that could solubilize Zn/Cu-assembled A deposits in
vivo and inhibit A redox chemistry. CQ was used exten-
sively as an oral antibiotic (Richards, 1971) before it was
withdrawn in the early 1970s due to overdose-associ-
ated neurological side effects that are now believed to
be preventable with B12 supplementation (Yassin et al.,
2000).
Here we report the effects of CQ (oral treatment) on
aged APP2576 Tg mice with advanced A deposition.
CQ treatment for 9 weeks markedly inhibited cerebral
A deposition by 375 g/g wet weight compared to
sham-treated controls. These changes were accompa-
nied by no adverse effects and a significant improve-
ment in scores on a general behavior rating scale. These
findings are strong support for the role of zinc and cop-
per interaction with A in the pathophysiology of AD
and indicate that the CQ class of agents could have
therapeutic utility in AD.
Results
We first studied CQ in filtration assay systems that we
previously used to identify several chelators that inhibit
and reverse Zn/Cu-induced aggregation of synthetic
A1-40 and A1-42 peptides in vitro (Atwood et al.,
1998, 2000; Bush et al., 1994a, 1994b; Huang et al.,
1997; Moir et al., 1999). CQ (2 M, in TBS, pH 7.4) was
significantly more effective than EDTA (2 M, in TBS,
pH 7.4) in dissolving A1-40 aggregates induced by ei-
ther Zn2 or Cu2 (Figure 1A). Neither chelator could
resolubilize A1-40 aggregates induced by incubating
the peptide at pH 5.5, which induces -sheet formation
(Wood et al., 1996) (Figure 1A).
Potential binding interactions of CQ with A were
studied by NMR spectroscopy of A1-28, which pos-
sesses the metal binding sites of A centered around
the 3 histidine residues (Atwood et al., 1998; Bush et
al., 1994a), as well as a domain (residues 17-21) that
binds to peptide fibrilization inhibitors (Soto et al., 1996).
When one equivalent of Cu2 was added to A1-28 (1
mM in aqueous solution), the metal bound to the histi-
dine residues as evidenced by broadened NMR peaks
Figure 1. Interactions of Clioquinol with A In Vitroobserved in the differences between the spectra shown
(A) Effects of CQ upon the retention of A1-40 aggregates inducedin Figure 1B, scans A and B. The addition of CQ to this
by Zn2, Cu2, or pH 5.5. The procedure was a modification of onesolution restored the peaks that had been broadened
which we have previously reported (Moir et al., 1999). Values arein the starting NMR spectrum of A (Figure 1B, scan C)
expressed as a percentage of the amount of aggregated A de-
due to the presence of copper. This result is consistent tected after washing with TBS pH 7.4 vehicle alone (100%), repre-
with CQ removing bound copper from A. There were sented as mean  SD, n  3.
no changes to the NMR spectrum of A1-28 upon addi- (B) NMR spectroscopy of A1-28 in the presence of Cu2 and CQ.
A, Spectrum of A1-28 in saline buffer (pH 6.9) showing the peakstion of CQ alone, and addition of CQ to either aqueous
due to the methyl groups of Val-12, -18, -24 and Leu-17. B, Spectrumor DMSO solutions of A1-40 (0.3 mM) did not affect
of sample in A after adding Cu2. C, Spectrum of the sample in Bthe NMR spectrum (data not shown), suggesting that
after adding CQ. The lower resolution of the spectrum in C is due
CQ does not act as a fibril inhibitor by binding the pep- to the presence of aggregated material in the sample.
tide. NMR spectra of CQ alone were recorded and found (C) Enhanced extraction of A from human AD-affected postmortem
not to be perturbed by the addition of A1-40 (0.3 mM), brain tissue following homogenization in the presence of clioquinol.
The upper panel shows a Western blot (using WO2, which detectsconfirming that CQ does not bind to the peptide.
both A1-40 and A1-42) of the soluble fraction of frontal lobe, theIn order to confirm that CQ, like other Cu2/Zn2-selec-
same sample of which had been divided and homogenized in thetive chelators, could chemically solubilize A deposits
presence of increasing concentrations of CQ (in PBS, pH 7.4). Corre-
in AD (Cherny et al., 1999), we homogenized postmortem sponding densitometric quantification is shown in the lower panel.
human brain samples affected by AD in the presence The data are representative of n  9 AD cases.
of CQ. We found that there was a concentration-depen-
dent increase in A liberated into the soluble phase,
typically200% in the presence of0.4 M CQ (Figure
-Amyloid Inhibition with a Cu/Zn Chelator
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1C, typical of 9 cases). The A liberated by treatment appreciated when contrasted to the average levels of
A in the pellet fraction of AD-affected cortical tissuewith CQ was detected using monoclonal antibody WO2
(which detects A40 and A42 at an epitope between (20 g/g wet weight) (McLean et al., 1999) measured by
the same technique.residues 5–8, Figure 1C), and a similar proportional in-
crease in A40 and A42 species compared to the base- Quantification of soluble cerebral A levels in the sam-
ples revealed a significant increase in the levels of solu-line amounts extracted by PBS was determined by blot-
ting with G210 (specific for Ax-40) and G211 (specific ble A in the brains of the CQ-treated mice (0.25  0.02
mg/g protein [52%, p  0.004], 8.06  0.81 g/g wetfor Ax-42) (Ida et al., 1996) (data not shown). The effect
of CQ in enhancing A liberation in this assay is compa- weight [44%, p  0.014]) compared to sham-treated
controls (0.16  0.01 mg/g protein, 5.61  0.41 g/grable to the effect we previously reported in the same
system for bathocuproine, a Cu chelator (Cherny et al., wet weight) (Figure 3B). This rise represented a small
(1%) increase in the contribution of soluble A to total1999). Similar to the effects of homogenizing the brain
sample with other Cu/Zn-selective chelators (Cherny et cerebral A content (CQ-treated 2.10% 0.19%, sham-
treated 0.81%  0.09%; Figure 3C). However, the in-al., 1999), the majority (90%) of the A remains in the
pellet phase after one extraction with CQ. However, re- crease is soluble A levels is very modest (0.6 M, as-
suming one g wet weight  1 ml) compared to thepeated extractions continue to liberate approximately
the same proportion of A so that eventually the majority profound decrease in sedimentable A (approximately
90M) in the cerebrum in the CQ-treated mice. Solubleof the A in the tissue is solubilized (data not shown).
In view of these results, we performed a pilot study APP (sham, 31.9  2.4 g/g wet weight; CQ, 34.9  2.5
g/g wet weight; p0.41) and pellet APP (sham, 138.2of CQ treatment in the APP2576 Tg mice (Hsiao et al.,
1996). We first compared the effects of CQ and triethyl- 19.8g/g wet weight; CQ, 172.8 21.4g/g wet weight;
p  0.25) levels in these samples were not significantlyene tetramine (TETA, a hydrophilic Cu/Zn-selective che-
lator) on a cohort of 12-month-old APP2576 mice. The different in the CQ compared to the sham-treated co-
horts, indicating that the decrease in total A levelsdrugs were delivered by gavage daily for 12 weeks.
The animals were sacrificed and brain A levels were induced by CQ was not due to decreased APP pro-
duction.appraised. There was a mean decrease in the pellet
fraction of cerebral homogenates from the animals Accompanying these changes was a significant de-
crease (p  0.04) in the immunohistochemical amyloidtreated with CQ 2 mg/kg/d group (275 38g/g protein,
n  6) that did not reach statistical significance com- plaque surface area in the CQ-treated mice (13.0  1.5
2/100 2) compared to the sham-treated mice (17.3 pared to sham-treated controls (316  81 g/g protein,
n  6). However, there was a significant 65% decrease 1.3 2/100 2) (Figure 3D). There were no correlations
between the levels of soluble A, total A, soluble/totalin the levels of sedimentable A in the mice treated with
CQ 20 mg/kg/d (110  56 g/g protein, mean  SE, A ratio, or plaque surface area in either the CQ-treated
mice or sham-treated mice (or combined groups), whichn  5, p 	 0.01). Intriguingly, two animals in the CQ 20
mg/kg/d treatment group were found to have no mea- is in agreement with our previous findings of a lack of
relationship between soluble A, sedimentable A, andsurable A in the brain pellet fractions and no detectable
amyloid pathology in their neocortex or cortical blood plaque surface area in postmortem AD brain specimens
(McLean et al., 1999).vessels (Figure 2). Transgenic status and the overex-
pression of APP were reconfirmed in all animals. TETA As a marker of synaptic loss, cerebral synaptophysin
levels were assayed and determined to be unaffectedat 18 mg/kg/d had no significant effect on sedimentable
A levels either alone (494  56 g/g protein, n  5) or (sham  788  102 U/g protein, n  14; CQ  720 
63 U/g protein, n  13, p  0.57). There was also anin combination with CQ 2 mg/kg/d (342  114 g/g
protein, n  5). insignificant 20% decrease in hippocampal cells stain-
ing positively for glial fibrillary acidic protein (GFAP) inTo further test whether the amyloid-clearing effects
of CQ, we next studied the effects of CQ at a higher the CQ-treated mice (sham  27.0  4.3 cells/hpf, n 
13; CQ  21.6  3.7, n  14, cells/hpf, p  0.34). Thedose (30 mg/kg/d) in a larger cohort (n 20 on drug, n
19 sham-fed transgenic controls) of older (21 months) brain masses and protein concentrations were un-
changed in the CQ-treated mice compared to the sham-APP2576 mice using more detailed analysis. We utilized
a similar blinded protocol, in which the animals were treated controls (sham  0.262  0.015 g wet weight/
hemisphere, 23.42  1.08 mg protein/hemisphere, n administered CQ by daily gavage for a shorter interval
(9 weeks), since the animals were of advanced age. 14; CQ  0.279  0.005 g wet weight/hemisphere,
20.95  1.17 mg protein/hemisphere, n  14, p  0.1).There were similar numbers of male and female mice in
each treatment group after randomization. Measure- No significant correlations were observed between syn-
aptophysin or GFAP levels and levels of A, plaque, orment of cerebral A levels at the completion of the study
indicated that there was again a marked and significant total protein.
Serum levels of A were significantly decreaseddecrease in pellet A in CQ-treated mice. The levels of
pellet A in sham-treated mice were 7.48  0.73 mg/g (24%, p  0.04) in the CQ-treated animals (115  8
ng/ml) compared to sham-treated controls (152  18protein, 770.0 68.6g/g wet weight, and in CQ-treated
mice were 4.44 0.36 mg/g protein [41% decrease, p ng/ml) (Figure 3E). There was a significant correlation
(R2  0.2, p  0.03) between serum A levels and total0.001], 394.6  39.6 g/g wet weight [49% decrease,
p  0.0001] (Figure 3A). The difference in sedimentable cerebral A levels of the combined groups.
To determine the effects of treatment with CQ, weA of 375 g/g wet weight of cerebral tissue after
only 9 weeks of treatment with CQ indicates a profound also measured metal levels (Al, Co, Cr, Cu, Fe, Mn, Pb,
Se, Zn) in the soluble and sedimented fractions of brainalteration in the rate of A accumulation, which can be
Neuron
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Figure 2. Initial Study of the Effects of Oral
Treatment of 15-Month-Old APP2576 Trans-
genic Mice with Clioquinol
Immunohistochemistry of A deposits in the
hippocampal region of two 15-month-old
APP2576 mice treated with either CQ 20 mg/
kg/day (A) (representative of two animals) or
sham-treated (B) (representative of three ani-
mals). The figure is typical of 4 sections ana-
lyzed throughout each brain. Size bar 
50 m.
and peripheral organ homogenates from the 21-month- out the study were not significantly different until day
53 of the study, when it observed that the mice treatedold APP2576 study cohort. We detected significant in-
creases in Cu (19%, 4.7 M, p  0.007) and Zn with CQ maintained their weight, whereas the weights of
the sham-treated animals declined so that the surviving(13%, 9.6 M, p  0.006) levels in the soluble cere-
bral fractions of the CQ-treated mice (Table 1), but no CQ-treated mice became significantly heavier (37.41 
5.09 g) than the sham-treated mice (33.19  4.05 g,changes for any of the other metals measured. There
was no significant change in any metal levels in the p 	 0.05) at day 53 (Figure 4A). CQ did not significantly
affect the longevity of the mice, as the mean survivalextracted centrifugation pellet fraction of the cerebral
homogenates of the CQ-treated mice. There was a sig- intervals of the CQ-treated mice (53.8  4.3 d) and the
sham-treated mice (57.2  2.9 d) as well as survivalnificant 24% increase in Co in the soluble fraction of
the liver homogenates of the CQ-treated mice, as well curves (Figure 4B) were not significantly different (log
rank survival distribution  0.35, p  0.55). Therefore,as significant 15% increase in Zn content of the kidney
pellet fraction. There were no other differences in metal there was no gross evidence of toxicity for CQ treatment
at this dose.levels in the liver and kidney samples from the CQ com-
pared to the sham-treated animals. There were also no Because of the advanced age of these animals, water
maze testing was not possible. However, to gauge grosssignificant correlations between the levels or ratios of
the various metals with the levels or ratios of the A physiological changes caused by CQ on the treated
mice, we devised a 5 point integer scale that subjectivelylevels in the soluble and sedimented brain fractions, or
with the plaque surface area. There was a significant rated a combination of general features (motor activity,
alertness, and general health signs) and was adminis-linear correlation between Cu and Zn levels in the cere-
bral fractions of the combined (CQ sham) cohort (R2 tered by a blinded operator every day to each individual
mouse. There was a decline in the readings of the sham-0.2, p  0.03).
As an appraisal of the potential toxicity of CQ, we treated mice that plateaued after 16 days of treatment
(Figure 4C), which may have been due to repeated han-reviewed the vital data of the two cohorts of 21-month-
old APP2576 mice. Weight measurements of the sham- dling of the animals. In contrast, after the same initial
decline as the control mice, the CQ-treated mice thentreated and CQ-treated mice taken at intervals through-
-Amyloid Inhibition with a Cu/Zn Chelator
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Figure 3. Effects of Oral Clioquinol Treat-
ment on A Metabolism in 21-Month-Old
APP2576 Mice
(A and B) (A) Total and (B) soluble A levels
from cerebral homogenates of sham-treated
mice and mice treated with clioquinol (30 mg/
kg/day, CQ).
(C) Proportion of soluble A compared to to-
tal A (in percentage of mg/g wet weight val-
ues) in sham-treated compared to CQ-
treated mice.
(D) Immunohistochemical plaque surface
area from fixed cortical tissue of sham-
treated mice and CQ-treated mice.
(E) Serum A levels in sham-treated com-
pared to CQ-treated mice.
recovered after 16 days, and their readings plateaued of CQ treatment was sustained from day 17 for each of
the 46 remaining days of the study.at a consistently higher mean score on this index than
those of the sham-treated mice. This apparent benefit The plateauing in mean scores for each group follow-
Table 1. Effects of Oral Clioquinol Treatment on Distribution of Metals within Selected Tissues of 21-Month-Old APP2576 Mice
Co (ng/g) Cu Zn
C CQ C CQ C CQ
Brain (sol.) 18.1 12.3 1.70 2.02** 4.83 5.45**
Brain (pel.) 18.6 15.9 1.32 1.39 3.86 4.25
Liver (sol.) 27.1 35.7* 3.26 3.41 29.6 34.0
Liver (pel.) 34.6 35.4 3.05 2.95 14.1 15.7
Kidney (sol.) 74.5 91.6 0.73 0.82 6.61 7.30
Kidney (pel.) 66.4 62.9 2.25 2.34 7.96 9.12*
Metal levels (averages in ng or g/g wet weight) in tissues where significant differences are noted between the C and CQ groups. Two-tailed
t tests were performed on differences between the mean values from the sham-treated (C) compared to clioquinol-treated (CQ) samples.
Significant differences in the mean values are represented by data in bold; asterisk, p 	 0.05, and double asterisk, p 	 0.01. No significant
differences were found for levels of Al, Cr, Fe, Mn, Pb, or Se.
Neuron
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improvement in the surviving CQ-treated mice was sig-
nificant [F(61, 1525)  2.4, p 	 0.0001; observations
included from day 0 until completion]. Although this
scale is not a linear gauge of deterioration, the differ-
ences between the integer scores in the treated and
untreated groups support the conclusion that CQ in-
duces a conspicuous improvement in the health of the
transgenic mice.
Discussion
Taken together, our findings indicate that CQ treatment,
for as little as 9 weeks, inhibits and possibly reverses
accumulation of A deposits in APP2576 transgenic ani-
mals. Our in vitro findings that CQ reverses Cu2- and
Zn2- induced Aaggregates (Figure 1A) and, at concen-
trations as low as 400 nM, solubilizes A deposits in
AD-affected postmortem brain tissue (Figure 1C) sup-
port the likelihood that the in vivo effect we observed
was due to interdiction of the interaction of these metal
ions with cerebral A. This likelihood is further sup-
ported by the observation that CQ complexes with Zn2
in the brain (Shiraki, 1979), especially in areas enriched
in synaptic vesicular zinc such as the temporal lobe,
which is severely affected by amyloid deposition. The
alternative possibility of CQ acting as a fibril chain-
breaker was not supported by NMR spectroscopy (Fig-
ure 1B).
The possibility that CQ exerted its effects by chelating
Fe2/3 (Kidani et al., 1974) cannot be excluded, since
Fe2/3 precipitates A (less effectively than Zn2 or
Cu2) (Atwood et al., 1998) and is also found to be en-
riched in plaque (Lovell et al., 1998). But unlike the Zn
Figure 4. Effects of Clioquinol Treatment on the Systemic Health of and Cu levels in the brain, treatment with CQ did not
21-Month-Old APP2576 Mice alter Fe levels in the APP2576 cohort. Also, chelators
Parameters measured over the duration of the study: (A) weight that solubilize A from postmortem AD cortical speci-
(mean SD; asterisk, significant difference in mean weights in each
mens appear to redistribute Zn and Cu, but not Fegroup greater than the difference at day 0, p 	 0.05; solid symbols
(Cherny et al., 1999). It is unlikely that the decrease inare CQ treated); (B) survival curves (dashed is CQ treated); (C) gen-
A accumulation was due to decreased A synthesiseral impairment (blinded subjective rating scale). Mean daily scores
(SEM) for the CQ-treated and sham-treated groups are indicated. caused by CQ-associated toxicity, since there was no
decrease in brain APP levels, brain synaptophysin levels
were not decreased, and the CQ-treated mice exhibited
signs of improved general health rather than signs ofing day 16 in Figure 3C is influenced by the integer
scoring and nonlinear nature of the rating scale. A further toxicity (Figure 4C).
TETA did not inhibit A deposition in this animalbreakdown of the daily scores (n 746 individual obser-
vations) for CQ-treated group from day 17 onward re- model. This may be because, unlike CQ, it is not a lipo-
philic molecule, and therefore may not be able to pene-vealed that 60.7% of the scores were 5 (out of 5, meaning
no apparent impairment), 32.0% were 4 (meaning minor trate the A deposits, or because the dose was insuffi-
cient. We have observed, however, that higher dosessigns of impairment), 6.6% were 3 (meaning periodic
signs of serious impairment), 0.7% were 2 (meaning of TETA (40 mg/kg/d) were rapidly toxic in non-Tg mice,
therefore limiting its testing. In contrast, CQ is rapidlypersistent signs of serious impairment), 0.0% were 1
(meaning moribund). In contrast, the statistical mode absorbed from the rodent gut with blood levels reaching
1–10 M within 1 hr of ingestion (Kotaki et al., 1983),for the sham-treated group was decreased to 4, with
only 30.6% of daily readings being 5, 48.4% were 4, and since it is hydrophobic, it passes rapidly into the
brain. CQ is rapidly excreted in the urine so that a bolus12.6% were 3, 7.0% were 2, and 1.3% were 1 (n  767
observations). Therefore, compared to sham-treated dose of clioquinol is almost completely removed from
the brain within 3 hr (Toyokura et al., 1975).animals, treatment with CQ doubled the incidence of
animals that appeared to be grossly normal (sham- Our results indicate that the beneficial effects of CQ
treatment contrast favorably with the popular A vacci-treated  30.6% of observations versus CQ-treated 
60.7%). Readings of 3 or less were relatively uncommon nation experimental treatment approach and with any
of the other reported candidate AD treatments testedbecause once the animals became serious impaired,
they usually died soon after. A two-way ANOVA with in adult transgenic mice. Schenk et al. (1999) reported
that total cerebral A (including A1-40 and A1-42) inrepeated measures on these results indicated that the
-Amyloid Inhibition with a Cu/Zn Chelator
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PDAPP mice was decreased by 7.0 g/g wet weight (at the effects of CQ treatment (25%, Figure 3D). However,
direct comparison between reports that use quantitative15 months of age) after 4 months of monthly inoculation
with synthetic A1-42 compared to sham-treated con- image capture analysis of plaque surface area is prob-
lematic for several reasons. The reports of A burdentrols, and by 13.8g/g (18 months of age) after 7 months
of monthly treatment. Monthly treatment with anti-A in units of surface area do not make reference to quanti-
tative standards that correspond to a degree of stainingantibody injections for 6 months induced an 8.9 g/g
reduction in total cerebral A1-42 in the same mouse intensity within a dynamic range. Therefore, the surface
area of the section that is adjudged as positive for Amodel at 15 months of age (Bard et al., 2000). Since
A1-42 represents 90% of total A species in this immunoreactivity is a product of where the software is
instructed to set the monochromatic threshold valuemodel (Johnson-Wood et al., 1997), the estimated de-
crease in total A reported by Bard et al. (2000) is 10 for a particular series of measurements. This threshold
value varies from report to report, usually dependingg/g. Recently, intranasal A immunotherapy has been
reported to induce a 1.5 g/g decrease in A in PDAPP upon the nonspecific background intensity of the prepa-
ration, and the set zero is therefore arbitrary. As a result,transgenic mice (Weiner et al., 2000), and a replication
of the original A immunization protocol (Schenk et al., separate studies of cortical A burden in the same
mouse model result in greatly different values. For exam-1999) failed to decrease total Abut did induce a marked
decrease in plaque surface area in TgCRND8 transgenic ple, Schenk et al. (1999) reported the mean area of corti-
cal 3D6 A immunoreactivity in sham-treated 18-month-mice (Janus et al., 2000).
In comparison, we found a 375 g/g reduction in ex- old PDAPP mice to be 4.87%, yet the same group using
the same methods subsequently reported that sham-tracted total cerebral Awith CQ treatment in 23-month-
old APP2576 mice. Although this 50% decrease com- treated younger (15-month-old) PDAPP mice have a
mean cortical 3D6 A immunoreactivity that is appar-pared to sham-treated controls is proportionally less
than the best reported effects of the A vaccination in ently much greater (19%) than the older animals (Bard
et al., 2000).older mice (60% and 80% decreases in 15- and 18-
month-old PDAPP mice, respectively) (Schenk et al., Furthermore, if the monochromatic threshold is set
too high, many of the samples in a treatment group1999), the absolute reduction in A induced by CQ is
30 times greater. Furthermore, the beneficial effect of will achieve readouts that are below the threshold of
detection, introducing artifactually decreased varianceCQ was achieved more rapidly with CQ (9 weeks) than
with the vaccine protocol (4 and 7 months). into the data from that group (because subzero values
will be read as zero, with no variance). To address thisLim et al. (2000) recently reported a decrease in total
A of 22 ng/cerebral hemisphere (untreated controls  problem, we set our threshold deliberately lower so that
we could appreciate the variance in the treatment (CQ)54.7 ng, ibuprofen treated  32.7 ng, approximately
40%) in the 2% SDS insoluble pellet fraction of 16- group, which may explain why we observed a 25%
decrease in plaque surface area but the decrease inmonth-old APP2576 mice treated for 6 months with ibu-
profen 56 mg/kg/d, an antiinflammatory drug. Contrast extracted A was nearly twice as large (Figure 3, 50%).
As a result of the arbitrary setting of threshold floorof our results with this study is difficult since we mea-
sured A in PBS soluble and insoluble fractions; how- values for histological A immunoreactivity, the propor-
tional changes in plaque surface area values may notever, the PBS-insoluble values for our sham-treated
23-month-old APP2576 mice were 206  25 ng/hemi- correspond to the changes in extracted A levels. With-
out a means of standardizing such data, this method-sphere, and for CQ treated 110  11 ng/hemisphere, a
difference of 96 ng/hemisphere or approximately47% ological problem invalidates proportional comparisons
of plaque surface area with extracted A values and(p  0.002), achieved following 9 weeks of treatment.
The phosphatidylinositol kinase inhibitor wortmannin also disqualifies the reference of plaque surface area
changes in treated brains as a proportion of such sur-has been reported to prevent A accumulation (0.2g/g)
in the APP2576 mouse model treated for 4.5 months face area in untreated brains. Hence, we believe that
the commonly used description of proportional changesuntil 8.5 months of age (Haugabook et al., 2001). No
data is yet available on the effects of wortmannin on in immunohistochemical plaque surface area within or
between studies is an incorrect practice. Therefore, weAPP2576 mice of similar ages to the groups that we
studied. have reported absolute changes in plaque surface area;
the reduction in immunoreactive plaque surface areaCQ treatment was associated with absent histological
amyloid deposition in two of five 15-month-old Tg mice that we observed (4.3 2/100 2) was approximately the
same as that reported by Schenk et al. (1999) (4.8 2/(Figure 2). In our experience in examining A immunohis-
tochemistry in the brains of this APP2576 model, there 100 2), but additional controls would be necessary to
validate such a comparison.has been no instance where amyloid deposition is ab-
sent at 15 months of age (n 200 observations). Further These methodological issues may contribute to the
lack of correlation between extracted brain A valuesstudies will be necessary to determine whether CQ treat-
ment prolonged for greater than the 9 and 12 week and plaque surface area in human studies (McLean et
al., 1999) and in the current study. However, plaque mayintervals employed here might induce more instances
of complete clearing of amyloid, such as those seen in be a qualitative feature of A accumulation produced
by local neurochemical interactions, and not a strictthe treatment of amyloid-bearing transgenic mice inocu-
lated for 4–7 months with synthetic A1-42 (Schenk et product of A concentration. This would explain why
levels of A are elevated to the same extent in bothal., 1999). In relative terms, treatment with A immuno-
therapy or ibuprofen achieved greater proportional de- neocortex and basal ganglia in AD (McLean et al., 1999),
yet distinct plaques do not appear in the basal ganglia.creases in the surface area of A immunoreactivity than
Neuron
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The biochemical distinction between plaque and non- such as when postmortem AD-affected brain tissue is
treated with chelators (Cherny et al., 1999) like CQ (Fig-plaque A values could be important in evaluating ex-
perimental treatment approaches in transgenic mouse ure 1B). Therefore, the soluble A species that is ele-
vated following CQ treatment is either a nontoxic formmodels. For example, A vaccination has recently been
reported to decrease plaque surface area but not levels of A or its toxicity has been attenuated by reaction
with CQ.of total extracted A (Janus et al., 2000). In contrast,
the inability of CQ to resolubilize synthetic -sheet- The increase in the ratio of soluble to total A could
also represent a physiological normalization since, inmediated A aggregates (Figure 1A) may be compatible
with CQ impacting less on plaque deposition than on AD, this ratio falls (Cherny et al., 1999; McLean et al.,
1999), probably due to the reaction that drives the pre-diffuse A deposition (Figure 3). Therefore, the two pro-
posed therapies may be targeting different biochemical cipitation of the peptide in the disease. The CQ-associ-
ated rise in soluble A levels associated with a net de-forms of A. Both Janus et al. (2000) and our current
study report in vivo improvements in the treated animals crease in total A implies that the A deposits are
dissociating into the soluble phase. The detection ofso that the relationship between physiological deficits
and the accumulation of a specific species of A is likely elevated soluble A levels in the CQ-treated mice also
suggests that APP processing is not inhibited by CQto be complex.
Given the caveats in making comparisons between treatment. Therefore, in contrast to APP secretase inhib-
itors that decrease soluble A levels, the CQ treatmentthese studies (e.g., differences in transgenic mouse
models, differences in ages of cohorts, exponential ac- is expected to increase soluble A levels in the process
of reversing Adeposition. Further studies will be neces-cumulation of A as the animals age, differences in ex-
traction and assay procedures), it is not yet possible to sary to determine whether cerebral soluble A levels
will rise further or ultimately fall if A deposition wasdraw firm conclusions about the relative potencies of
CQ compared to other candidate treatment approaches. abolished by CQ, say as a result of more prolonged
treatment of the mice.Further side-by-side comparative studies are required
to achieve a true appraisal of the relative efficacies of Although treatment with a chelating agent may be
expected to deplete systemic metal levels causing ad-these various treatment approaches. Nevertheless, the
375 g/g reduction in total cerebral A that was verse effects, we found no depletion of peripheral metal
levels. This result is probably a reflection of the lowachieved with CQ is also meaningful because the con-
centration of total A (using similar assay methods) in affinity of CQ for Zn2 (K1  7.0) and Cu2 (K1  8.9) so
that once these metal ions are released from the cerebralAD-affected neocortex is only 20–30 g/g wet weight
(Cherny et al., 1999; McLean et al., 1999). We therefore amyloid mass, the affinity of the drug is too low to lead
to net metal excretion in the face of the homeostaticconclude from our results that CQ treatment at this dose
leads to a marked interruption in cerebral A accumula- response to maintain systemic metal levels. This result
suggests that the drug may induce remission of amyloidtion that could potentially impact upon A accumulation
in AD, and that the dose of CQ per kilogram used in deposition in AD itself without necessarily depleting tis-
sue metal levels.this study might exceed what would be needed for a
beneficial effect in human clinical trials. The 15% elevation in soluble Zn (9.6 M) and Cu
(4.7 M) levels in the brain after treatment with CQCQ treatment of the 21-month-old APP2576 mice ele-
vated the concentration of soluble brain A by 3.45 g/g (Table 1) is surprising since CQ treatment of nontrans-
genic mice (10 mg/kg/d for 20 days) significantly de-wet weight (Figure 3B). Although this is a50% increase
in soluble A levels compared to untreated animals, creased (25%) brain Cu and Fe levels, although it did
not change Zn levels (Yassin et al., 2000). We hypothe-it represents only a 1% rise in total A levels (Figure
3C) and is overshadowed by the more profound (100- size that the rise in cerebral Zn and Cu levels in CQ-
treated APP2576 mice may reflect the tissue scavengingfold) decrease in insoluble A (375 g/g, Figure 3A)
leading to a net 50% decrease in total A burden. of A coprecipitated with Cu2 and Zn2 that is liberated
by the action of CQ; the A is proteolytically degradedThere is some concern that elevating soluble A levels
may contribute to pathophysiology since we (McLean while the metals are stored transiently in the metallothio-
nein pool. It is also possible that CQ treatment has ad-et al., 1999) and others (Lue et al., 1999; Wang et al.,
1999) have reported that the levels of soluble A in AD justed metal homeostasis in the tissue by altering the
turnover of A and APP. Studies of APP knockout micecerebral tissue correlate with neuritic change, neurofi-
brillary tangle load, and inversely correlate with life ex- indicate that A and/or APP could be involved in Cu,
Zn, and Fe homeostasis in the cerebral cortex and pe-pectancy, suggesting that soluble forms of A may me-
diate toxicity in AD. Furthermore, toxic soluble forms of ripheral tissue, as evidenced by significantly increased
Cu levels, and a trend toward increased Zn and Fe levels,A have been purified from AD-affected brain (Kuo et
al., 1996). However, there was no evidence in the current in these tissues (White et al., 1999). Therefore, APP2576
mice that overexpress APP may be expected to havestudy that the increase in soluble A was accompanied
by any adverse effects, abbreviated life span, or synap- constitutively decreased levels of these metals. If A
plays such a role in metal homeostasis, CQ may indi-tic loss. Nontoxic soluble A species are found in normal
brain tissue (Cherny et al., 1999; McLean et al., 1999). rectly correct the depletion of metals in the transgenic
tissue by facilitating A turnover. In agreement with thisAlso, not all forms of A are toxic even in the AD-affected
brain since there is a zinc-bound form whose abundance interpretation of the findings that clioquinol increases
copper levels in APP2576 transgenic mice by correctingis inversely correlated with oxidative damage to neuropil
(Cuajungco et al., 2000). It may be this form that is a defect in copper homeostasis, we have recently found
that these mice, as well as transgenic mice expressingliberated into the soluble phase upon CQ treatment,
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the carboxy-terminal 100 amino acids of APP, both de- induced by acute overdoses in excess of 7.5 g have
velop significantly decreased copper levels in brain tis- been reported (Baumgartner et al., 1979). Conversely,
sue as they age (C. Maynard, R.A.C., C.L.M., A.I.B., R. 25% of patients with SMON (in a sample of 2465 from
Cappai, and Q.X. Li, unpublished data). This implicates Japan) had never taken CQ (Nakae et al., 1973). In the
the turnover of A itself in sustaining brain copper levels. 1960s, the per capita consumption of CQ was higher in
CQ-treated animals did significantly better than sham- several other countries than the consumption in Japan.
treated controls in an index of general impairment and However, until 1975 there were 10,000 cases of SMON
also maintenance of body weight (Figures 4A and 4C). in Japan, while there were only 220 cases identified in
Despite being a crude instrument, the impairment index the rest of the world. Therefore, it is possible that local
that we used detected a highly significant improvement demographic factors prevalent in Japan at the time may
in CQ-treated versus sham-treated mice. Further studies have predisposed this population to develop SMON.
with more precise cognitive tests in younger animals One possibility is that the Japanese were endemically
capable of maze tasks are needed to determine whether B12 deficient as a consequence of their diet in the post-
this effect is due to systemic health effects or specific war years and that this was the predisposing factor to
cognitive effects. Since clearance of A accumulation SMON. CQ was commonly used to treat gastrointestinal
(by vaccination) is associated with improved perfor- symptoms in an unregulated manner in Japan in that era,
mance on cognitive testing of AD transgenic mice, we and SMON usually begins with symptoms of abdominal
predict that the clearance of A by CQ will also be pain and diarrhea, therefore overdosing in a B12-defi-
accompanied by gains in cognitive performance. Never- cient population may have exaggerated the incidence
theless, our findings that the general well being of the of SMON in Japan. In light of this possible explanation
animals improved with treatment raise the concern that for the association of CQ with SMON, coadministration
studies of candidate treatments in transgenic mice will of vitamin B12 is part of the phase two clinical trial that
need to control for general health effects when testing is currently in progress (C.L.M. and A.I.B., unpublished
performance in maze tasks. Improved maze perfor- data). A completed phase one clinical trial of CQ with
mance may be a reflection of improved general health B12 supplementation in AD patients revealed no ad-
or alertness, and not necessarily of improved selective verse systemic, neurological, or cognitive effects (C.G.
memory function. The blinded index that we employed Gottfries and M.X., unpublished data). Our current find-
is a facile and inexpensive means of introducing such ings indicate that CQ and its derivatives, or other hy-
a control. drophobic chelators, merit further investigation for their
We have shown that treatment with a lipophilic Zn/ therapeutic utility in the prevention and treatment of AD.
Cu chelator that crosses the blood-brain barrier attenu-
ates A deposition in a mouse model for AD, encourag- Experimental Procedures
ing us to translate this novel approach into the clinical
Effects of Chelators on Metal-Induced A Aggregationsetting. Our results may explain how desferrioxamine,
A1-40 (10 ng in 200 l) aggregation was induced by incubation (30a parenteral chelator with affinities for Cu2, Zn2, Fe3,
min, RT) with ZnCl2 (25 M in TBS, pH 7.4), CuCl2 (5 M in TBS, pHand Al3, may have acted to inhibit the progression of
6.8), or acidic conditions (pH 5.5, MES buffered saline). AggregatesAD in a clinical trial (Crapper McLachlan et al., 1991). were transferred to a 0.2  nylon membrane by filtration using a 96-
Our results suggest that CQ may be suitable for testing well ELIFA apparatus (Pierce). The aggregates were then washed
in clinical trials in AD patients. The recommended dose (200 l/well) with TBS alone, TBS containing 2 M EDTA, or TBS
of CQ when it was prescribed as an antiamebic was with 2 M CQ. The membrane was fixed, probed with the anti-A
monoclonal antibody 6E10 (Senetek), and developed for exposure500 mg 3–4 times/day (20 mg/kg/d), which is a weight-
to ECL film. Quantification of retained, aggregated A was per-normalized dosage level that achieved inhibition of A
formed by densitometry, calibrated against known amounts of thedeposition in our current studies. A caveat in the clinical
peptide.
use of CQ is that it has been associated with subacute
myelo-optic neuropathy (SMON), an uncommon neuro-
NMR Spectroscopy
logical syndrome largely confined to Japan (Tsubaki et Six hundred megahertz 1H NMR spectra were taken of 0.3–1 mM
al., 1971). A causal relationship between CQ and SMON A peptides in 50 mM phosphate buffer (pH 6.9) 100 mM NaCl, 10%
was never proven (Clifford Rose and Gawel, 1984; 2H2O at 271
K, using a Bruker DRX-600 instrument. CQ was first
dissolved in DMSO and then added at 800 M to ensure that theMeade, 1975), but the relatively low benefit of the drug
solution was saturated with soluble CQ. The maximal soluble con-balanced against the postulated risk of such a serious
centration of CQ prepared in this manner was determined to beside effect led to its worldwide withdrawal in the early
100 M, so an aqueous suspension was formed. NMR peaks due1970s. Our current findings suggest that a reexamination
to soluble CQ were detectable despite the presence of the majority
of this drug and its side effects may be warranted. of the CQ being in suspension.
CQ was used extensively for 20 years before the first
case of SMON was described, and before its retirement, Mice Studies
the drug was used for 500 million patient days as an All mice were housed according to standard animal care protocols,
antibiotic with a very favorable safety profile. SMON fed ad libitum, and maintained in a pathogen-free environment at
the MGH Neuroscience Center. The transgenic status of all animalsresembles an accelerated form of subacute combined
was confirmed by PCR of tail snips, using the 3UTR of the hamsterdegeneration due to vitamin B12 deficiency, and admin-
cosmid PrP vector as a hybridization probe, and for overexpressionistration of CQ to normal mice has been reported to
on the APP transgene by Western blot (22C11) of postmortem brain
deplete brain and serum levels of vitamin B12 (Yassin tissue. The colony was maintained by Charles River Laboratories
et al., 2000). Nevertheless, no clear relationship has been by crossing female Tg (HuAPP695.SWE)2576 with B6SJLF1/J males
identified between CQ dose and the risk for SMON in (Jackson Labs). The animals were randomized for therapy trials,
coded, and the operators and data analysts remained double blindhumans. Six cases of encephalopathy (but not SMON)
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to which treatment (or placebo) they received, until the code was yielded further solubilization of A from the formic acid “insoluble”
pellet fraction (Harigaya et al., 1995; Tamaoka et al., 1994).broken at the completion of data collection. The treated animals
were delivered, the chelator dissolved in 0.05% carboxymethylcellu- Furthermore, the Roher laboratory recently published that the
brain A deposits in the APP23 transgenic mouse model for Alzhei-lose (Sigma) by daily gavage, and the untreated controls were ga-
vaged with the placebo vehicle alone. The mice did not receive B12 mer’s disease can also be fully extracted with SDS and, unlike hu-
man brain A deposits, do not require FA treatment to be liberatedsupplementation.
The choice of dose of CQ for these studies was based upon pilot (Kuo et al., 2001). Our own methodological experiments confirmed
a similar observation in the brains of APP2576 mice. We found thatstudies and a review of the literature. Preparatory studies deter-
mined that 4-month-old nontransgenic mice tolerated CQ at 40 mg/ in mice with advanced amyloid pathology (18–20 months), extraction
of the brain homogenate into 8% SDS was 100% efficient, leavingkg/day for 7 days with no apparent adverse effects. An SMON-like
syndrome can be induced in dogs by sustained doses of CQ (150 no FA-extractable A. This suggests, in agreement with Kuo et al.
(2001), that the A deposits in the transgenic mouse model containmg/kg/day), but mice and other rodents are far less susceptible to
this syndrome (Tateishi and Otsuki, 1975). To minimize the chance less oxidative modifications than the A that comprises amyloid
in the human pathology and hence is more readily extracted byof neurological side effects in our studies, we chose doses of 30
mg/kg/d or less for periods no greater than 12 weeks. detergents. Therefore, apart from the pilot study of chelation treat-
ment, brain homogenate samples were extracted into SDS sample
buffer for Western blot.Mouse Data Collection
Histological sections of whole brain were prepared and the pro-In the study of 21-month-old APP2576 mice, the animals were exam-
portional surface area of amyloid plaques estimated by computer-ined daily by a blinded operator, and a measurement of each ani-
assisted immunohistochemical quantification (using monoclonal an-mal’s general behavior in its cage was taken by observation based
tibody 1E8), as described previously (McLean et al., 1999). Sectionsupon a subjective 5 point rating scale, where 5 is alert, grooming,
of the hippocampus were also stained with a monoclonal antibodynormal withdrawal response upon handling, and no obvious motor
against glial fibrillary acidic protein (DAKO) and the number of cellsabnormality; 4 is either distressed or lethargic, not grooming, lost
in the pyramidal layer staining positively per high-powered field (hpf)withdrawal response upon handling, but no motor abnormality; 3
was determined (n 3 fields, n 3 sections). The operator remainedis periodic obvious motor abnormality (paresis, spinning, tremor,
blind to the CQ treatment status of the tissue. Data from the treatedrigidity); 2 is persistent motor abnormality or cachexia; and 1 is
and untreated animal groups were analyzed by two-tailed t test.moribund. The animals were also weighed at intervals. Equality of
survival distributions was statistically tested by log-rank analysis. All
Metal Quantificationstatistical analyses used Systat 9.0 (SPSS, Inc.). At the completion of
Aliquots were taken from the supernatant samples of the tissueall studies, the animals were anesthetized, a blood sample obtained,
homogenates and diluted in 1% HNO3. The pellets were freeze-driedcardiac-perfused with cold saline, and the brain and peripheral or-
and digested in 300 l HNO3, followed by 300 l of H2O2 at 70
C,gans removed. The left cerebral hemisphere was fixed in 4% para-
and further diluted in 1% HNO3 for analysis by inductively coupledformaldehyde, and the right hemisphere (without cerebellum) and
plasma mass spectrometry (ICP-MS). ICP-MS was performed usingremaining tissues were weighed and snap frozen in liquid nitrogen.
an Ultramass 700 (Varian, Vic., Australia) in peak-hopping mode with
spacing at 0.100 AMU, 1 point per peak, 50 scans per replicate, 3
A, APP, Synaptophysin, and GFAP Analyses replicates per sample. Plasma flow was 15 L/min with auxiliary flow
Snap-frozen tissues were thawed and homogenized in PBS (pH 7.4, 1.5 L/min. RF power was 1.2 kW. Sample was introduced using a
2 ml) and centrifuged at 100,000  g for 30 min. A in the superna- glass nebulizer at a flow of 0.88 L/min. The apparatus was calibrated
tants (soluble), the pellet, in an aliquot of homogenate (total), and using a 1% HNO3 solution containing Cu and Zn at 5, 10, 50, and
in serum, was quantified by Western blot using WO2, an anti-A 100 ppb with Y89 the internal standard for all isotopes of Cu and
monoclonal antibody that detects all forms of full-length A, cali- Zn. Metal values are mean g/g wet weight of the original tissue
brated with known quantities of synthetic A, as previously de- sample. Two-tailed t test assuming unequal variances was per-
scribed (Cherny et al., 1999; McLean et al., 1999). APP was quantified formed on differences between the mean values from the untreated
by Western blot from the same samples using 22C11 (Boehringer), (C) compared to clioquinol-treated (CQ) samples.
which detects both the transgene-expressed human APP as well
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Formic acid extraction of tissue, while efficient, is problematic
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since the procedure chemically modifies A (formication) and also
requires the samples to be laboriously neutralized before PAGE
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